Overview

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
2016-03-19
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess pharmacodynamics, pharmacokinetics, and safety of ASP1941 in patients with type 1 diabetes mellitus when administered once daily (q.d.) for 2 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Ipragliflozin